Filter by: patients
Home > Community Treatment Reports and Side Effects > Epanutin caps Treatment Report
What is Epanutin caps?

Epanutin is a brand name for the drug Phenytoin, a commonly used antiepileptic. Phenytoin acts to damp the unwanted, runaway brain activity seen in seizure by reducing electrical conductance among brain cells by stabilizing the inactive state of voltage gated sodium channels.

Reported Purpose & Efficacy

Reasons and Efficacy
Purpose # of patients
# of patients with evaluations Efficacy
Major
Moderate
Slight
None
Can’t tell
Pain 1 1 Efficacy_major
Fasciculations 1 0
Epilepsy 1 0
Cramps in legs 1 0
Cramps in calf muscles 1 0

See 1 patient currently taking Epanutin caps

Mouse over the table for more information

Reported Side Effects

Side effects as an overall problem

Severe
 1
Moderate
 0
Mild
 0
None
 0

Commonly reported side effects, conditions, and hospitalizations associated with Epanutin caps

Weakness in legs 1
Balance problems 1

Reported Dosages

  100 mg daily 300 mg daily
  1 Number of Patients: 1 1 Number of Patients: 1  

Reported Stop Reasons

Why Patients Stopped Taking Epanutin caps (multiple reasons could be selected)
Reason # Patients Percentage of patients
Side effects too severe 1   Side effects too severe: 100%

See all 1 patient who’ve stopped taking Epanutin caps

Reported Duration See details about how long patients take this treatment ▼

Currently Taking Epanutin caps

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0
0

Stopped Taking Epanutin caps

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0
0

Reported Adherence, Burden & Cost See details from patient evaluations ▼

Adherence

Taking treatment as prescribed

Adherence of Epanutin caps

Always
 1 100%
Usually
 0 0%
Sometimes
 0 0%
Never
 0 0%

Burden

Difficulty being on treatment

Burden of Epanutin caps

Very
 0 0%
Somewhat
 0 0%
A little
 1 100%
Not at all
 0 0%

Cost

Paid out of pocket

Cost of Epanutin caps

$200+
 0 0%
$100-199
 0 0%
$50-99
 0 0%
$25-49
 0 0%
< $25
 1 100%

Report created on May 27, 2012.